IL300611A - Anti-C5 antibodies and methods for their use - Google Patents

Anti-C5 antibodies and methods for their use

Info

Publication number: IL300611A
Authority: IL; Israel
Prior art keywords: antibody; seq; amino acid; acid sequence; hvr
Prior art date: 2016-06-17

Application number

IL300611A

Other languages

English (en)

Hebrew (he)

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-17

Filing date

2017-06-16

Publication date

2023-04-01

2017-06-16 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2023-04-01 Publication of IL300611A publication Critical patent/IL300611A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Hematology (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

IL300611A 2016-06-17 2017-06-16 Anti-C5 antibodies and methods for their use IL300611A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2016120325		2016-06-17
PCT/JP2017/022253 WO2017217524A1 (en)	2016-06-17	2017-06-16	Anti-c5 antibodies and methods of use

Publications (1)

Publication Number	Publication Date
IL300611A true IL300611A (en)	2023-04-01

Family

ID=59969459

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL300611A IL300611A (en)	2016-06-17	2017-06-16	Anti-C5 antibodies and methods for their use
IL263657A IL263657B2 (en)	2016-06-17	2017-06-16	Anti-c5 antibodies and methods of use

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL263657A IL263657B2 (en)	2016-06-17	2017-06-16	Anti-c5 antibodies and methods of use

Country Status (19)

Country	Link
EP (1)	EP3472316A4 (ja)
JP (4)	JP6202774B1 (ja)
KR (2)	KR101852739B1 (ja)
CN (3)	CN115960223A (ja)
AU (1)	AU2017285763B2 (ja)
BR (1)	BR112018075688A2 (ja)
CA (1)	CA3021956A1 (ja)
CL (1)	CL2018003573A1 (ja)
CR (1)	CR20190013A (ja)
EA (1)	EA201990018A1 (ja)
IL (2)	IL300611A (ja)
MX (2)	MX2018015030A (ja)
MY (1)	MY187848A (ja)
PE (2)	PE20190394A1 (ja)
PH (1)	PH12018502354B1 (ja)
SG (2)	SG11201705584VA (ja)
TW (5)	TWI610941B (ja)
UA (1)	UA126561C2 (ja)
WO (1)	WO2017217524A1 (ja)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2006381T3 (en)	2006-03-31	2016-02-22	Chugai Pharmaceutical Co Ltd	PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
DK2202245T3 (en)	2007-09-26	2016-11-21	Chugai Pharmaceutical Co Ltd	A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
UA121453C2 (uk)	2008-04-11	2020-06-10	Чугей Сейяку Кабусікі Кайся	Спосіб одержання фармацевтичної композиції, яка містить антитіло
KR102385507B1 (ko)	2010-11-30	2022-04-12	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
JP6227191B1 (ja)	2014-12-19	2017-11-08	中外製薬株式会社	抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
US9765135B2 (en)	2014-12-19	2017-09-19	Chugai Seiyaku Kabushiki Kaisha	Anti-C5 antibodies
EP3394098A4 (en)	2015-12-25	2019-11-13	Chugai Seiyaku Kabushiki Kaisha	ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
US10633434B2 (en)	2016-06-14	2020-04-28	Regeneron Pharmaceuticals, Inc.	Anti-C5 antibodies
TWI610941B (zh) *	2016-06-17	2018-01-11	Chugai Seiyaku Kabushiki Kaisha	抗ｃ５抗體及使用方法
IL264626B (en)	2016-08-05	2022-07-01	Chugai Pharmaceutical Co Ltd	Composition for prophylaxis or treatment of il-8 related diseases
WO2019070714A1 (en) *	2017-10-04	2019-04-11	Alexion Pharmaceuticals, Inc.	ASSAY AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR THE TREATMENT OF PATIENTS WITH MEMBRANOPROLIFERATIVE GLOMERULONEPHRIPT
CN120571008A (zh)	2017-12-13	2025-09-02	瑞泽恩制药公司	抗c5抗体组合及其用途
KR20210055742A (ko)	2018-09-06	2021-05-17	더 트러스티스 오브 더 유니버시티 오브 펜실바니아	인간화된 항-c5 항체 및 이의 용도
EP3958901A4 (en) *	2019-04-24	2023-07-19	The Trustees of the University of Pennsylvania	BI-FUNCTIONAL HUMANIZED ANTI-C5 ANTIBODIES AND H-FACTOR FUSION PROTEINS AND THEIR USES
CN113563467A (zh) *	2020-04-28	2021-10-29	上海普铭生物科技有限公司	针对人补体蛋白c5的抗体及其应用
CN115803058A (zh) *	2020-07-15	2023-03-14	博奥信生物技术（南京）有限公司	结合c5的抗体及其用途
WO2022134047A1 (en) *	2020-12-25	2022-06-30	The Trustees Of The University Of Pennsylvania	Humanized anti-c5 antibodies and factor h fusion proteins and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0230985Y2 (ja)	1985-07-08	1990-08-21
US6074642A (en) *	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
DE60143859D1 (de)	2001-06-12	2011-02-24	Ericsson Telefon Ab L M	Synchronisation in einem terrestrischen umts-funkzugriffsnetzwerk (utran)
BRPI0211953B8 (pt)	2001-08-17	2021-05-25	Genentech Inc	anticorpo monoclonal ou fragmento de ligação a antígeno que se liga a c5 e c5a sem a prevenção da formação de c5b, linhagem celular, composição farmacêutica, bem como método in vitro para inibir a atividade de c5a e método de diagnóstico in vitro
JP4333939B2 (ja)	2001-08-27	2009-09-16	ロード・コーポレーション	トロリ線の吊架装置
DE10253331A1 (de)	2002-11-14	2004-06-03	Symrise Gmbh & Co. Kg	Verwendung von trans-Pellitori als Aromastoff
US7267849B2 (en)	2004-03-02	2007-09-11	Nitto Denko Corporation	Compensator for liquid crystal display
KR20080069889A (ko)	2007-03-20	2008-07-29	(주)화도	폴리에틸렌 관
KR20100015773A (ko) *	2007-03-22	2010-02-12	노파르티스 아게	Ｃ５ 항원 및 그의 용도
WO2008126921A1 (ja)	2007-04-11	2008-10-23	Sekisui Chemical Co., Ltd.	架橋ポリビニルアセタール樹脂の製造方法及び架橋ポリビニルアセタール樹脂
UA121453C2 (uk) *	2008-04-11	2020-06-10	Чугей Сейяку Кабусікі Кайся	Спосіб одержання фармацевтичної композиції, яка містить антитіло
ES2643411T3 (es) *	2008-08-05	2017-11-22	Novartis Ag	Composiciones y métodos para anticuerpos dirigidos a la proteína del complemento C5
KR20100054403A (ko)	2008-11-14	2010-05-25	삼성전자주식회사	온라인 공동 작문 장치 및 방법
KR20150002894A (ko) *	2010-03-11	2015-01-07	리나트 뉴로사이언스 코프.	ｐＨ 의존성 항원 결합을 갖는 항체
TW201206466A (en) *	2010-03-11	2012-02-16	Rinat Neuroscience Corp	Antibodies with pH dependent antigen binding
KR20110111007A (ko)	2010-04-02	2011-10-10	이화여자대학교 산학협력단	Ｌ／ｄ 광학변환 및 광학분할을 위한 옥타하이드로-바이나프톨 유도체
KR20110122011A (ko)	2010-05-03	2011-11-09	황보철종	매장 포인트 통합 관리 시스템 및 그 방법
EP2882778B1 (en) *	2012-08-13	2018-04-11	Regeneron Pharmaceuticals, Inc.	Anti-pcsk9 antibodies with ph-dependent binding characteristics
BR112015018438A2 (pt) *	2013-01-31	2017-07-18	Seoul Nat Univ R&Db Foundation	anticorpo contra c5 e método para prevenir e tratar doenças relacionadas a complemento
CA2897334A1 (en) *	2013-03-29	2014-10-02	Alexion Pharmaceuticals, Inc.	Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
NZ631007A (en) *	2014-03-07	2015-10-30	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
US9765135B2 (en) *	2014-12-19	2017-09-19	Chugai Seiyaku Kabushiki Kaisha	Anti-C5 antibodies
SI3390442T1 (sl) *	2015-12-18	2024-01-31	Chugai Seiyaku Kabushiki Kaisha	Protitelesa proti c5 in postopki uporabe
TWI610941B (zh) *	2016-06-17	2018-01-11	Chugai Seiyaku Kabushiki Kaisha	抗ｃ５抗體及使用方法

2017
- 2017-06-16 TW TW106120143A patent/TWI610941B/zh active
- 2017-06-16 TW TW112120479A patent/TW202337903A/zh unknown
- 2017-06-16 KR KR1020177020545A patent/KR101852739B1/ko active Active
- 2017-06-16 IL IL300611A patent/IL300611A/en unknown
- 2017-06-16 JP JP2017118226A patent/JP6202774B1/ja active Active
- 2017-06-16 CN CN202211018018.5A patent/CN115960223A/zh active Pending
- 2017-06-16 CR CR20190013A patent/CR20190013A/es unknown
- 2017-06-16 SG SG11201705584VA patent/SG11201705584VA/en unknown
- 2017-06-16 SG SG10201800265UA patent/SG10201800265UA/en unknown
- 2017-06-16 TW TW106141573A patent/TWI789369B/zh active
- 2017-06-16 EA EA201990018A patent/EA201990018A1/ru unknown
- 2017-06-16 MX MX2018015030A patent/MX2018015030A/es unknown
- 2017-06-16 IL IL263657A patent/IL263657B2/en unknown
- 2017-06-16 TW TW114113992A patent/TW202532438A/zh unknown
- 2017-06-16 PE PE2018003148A patent/PE20190394A1/es unknown
- 2017-06-16 EP EP17813418.5A patent/EP3472316A4/en active Pending
- 2017-06-16 KR KR1020187010179A patent/KR102226975B1/ko active Active
- 2017-06-16 PH PH1/2018/502354A patent/PH12018502354B1/en unknown
- 2017-06-16 CN CN201780036916.4A patent/CN109312326B/zh active Active
- 2017-06-16 MY MYPI2018002581A patent/MY187848A/en unknown
- 2017-06-16 BR BR112018075688-1A patent/BR112018075688A2/pt unknown
- 2017-06-16 CA CA3021956A patent/CA3021956A1/en active Pending
- 2017-06-16 PE PE2023002969A patent/PE20240825A1/es unknown
- 2017-06-16 CN CN202211023851.9A patent/CN115925922A/zh active Pending
- 2017-06-16 TW TW111107923A patent/TWI807666B/zh active
- 2017-06-16 WO PCT/JP2017/022253 patent/WO2017217524A1/en not_active Ceased
- 2017-06-16 AU AU2017285763A patent/AU2017285763B2/en active Active
- 2017-06-16 UA UAA201810992A patent/UA126561C2/uk unknown
- 2017-08-28 JP JP2017162934A patent/JP7032077B2/ja active Active
2018
- 2018-12-04 MX MX2023001360A patent/MX2023001360A/es unknown
- 2018-12-12 CL CL2018003573A patent/CL2018003573A1/es unknown
2022
- 2022-02-24 JP JP2022026406A patent/JP2022091748A/ja active Pending
2024
- 2024-04-30 JP JP2024073302A patent/JP2024102181A/ja active Pending

Also Published As

Publication number	Publication date
IL263657A (en)	2019-01-31
CN109312326B (zh)	2022-09-09
MY187848A (en)	2021-10-26
UA126561C2 (uk)	2022-11-02
SG10201800265UA (en)	2018-02-27
TWI807666B (zh)	2023-07-01
PE20190394A1 (es)	2019-03-13
TW201809000A (zh)	2018-03-16
CN115925922A (zh)	2023-04-07
BR112018075688A2 (pt)	2019-04-02
JP6202774B1 (ja)	2017-09-27
CL2018003573A1 (es)	2019-02-01
RU2019100222A (ru)	2020-07-17
AU2017285763B2 (en)	2024-02-01
IL263657B1 (en)	2025-08-01
KR20190009273A (ko)	2019-01-28
NZ748003A (en)	2024-12-20
TW201808996A (zh)	2018-03-16
JP2024102181A (ja)	2024-07-30
IL263657B2 (en)	2025-12-01
PH12018502354A1 (en)	2019-09-23
PE20240825A1 (es)	2024-04-18
WO2017217524A1 (en)	2017-12-21
CR20190013A (es)	2019-03-05
JP2018009021A (ja)	2018-01-18
TW202532438A (zh)	2025-08-16
JP2017226655A (ja)	2017-12-28
KR101852739B1 (ko)	2018-04-30
EA201990018A1 (ru)	2019-08-30
PH12018502354B1 (en)	2024-02-23
MX2018015030A (es)	2019-04-22
TW202239766A (zh)	2022-10-16
TWI789369B (zh)	2023-01-11
MX2023001360A (es)	2023-02-27
EP3472316A4 (en)	2020-01-08
TWI610941B (zh)	2018-01-11
CA3021956A1 (en)	2017-12-21
TW202337903A (zh)	2023-10-01
SG11201705584VA (en)	2018-05-30
KR102226975B1 (ko)	2021-03-11
RU2019100222A3 (ja)	2020-11-05
JP2022091748A (ja)	2022-06-21
JP7032077B2 (ja)	2022-03-08
AU2017285763A1 (en)	2018-11-08
CN109312326A (zh)	2019-02-05
CN115960223A (zh)	2023-04-14
EP3472316A1 (en)	2019-04-24

Publication	Publication Date	Title
US20240052021A1 (en)	2024-02-15	Anti-c5 antibodies and methods of use
CA3005592C (en)	2024-01-23	Anti-c5 antibodies and methods of use
KR102226975B1 (ko)	2021-03-11	항-c5 항체 및 사용 방법
HK40084339A (en)	2023-07-14	Anti-c5 antibodies and methods of use
HK40085591A (en)	2023-08-11	Anti-c5 antibodies and methods of use
EA041632B1 (ru)	2022-11-16	Антитела к с5 и способы их применения
HK1251942B (zh)	2022-05-06	抗-c5抗体及使用方法
HK1236962B (zh)	2021-08-13	抗-c5抗体及使用方法